Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5th International Scientific Congress on SMA (SMA Europe 2026; March 11-14, 2026).

GlobeNewsWire • Mar 5, 2026

Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 2, 2026

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA. “These data add to a growing body of evidence outlining the clinical.

Business Wire • Feb 27, 2026

Ionis Pharmaceuticals: Digesting Recent Events

Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 billion in peak annual product revenue, $2 billion in royalties, and $6 billion in milestones from its robust pipeline and partnerships. Management guides for cash-flow breakeven by 2028, with initial FY2026 guidance and a strong balance sheet supporting continued clinical advancement.

Seeking Alpha • Feb 27, 2026

Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.

Zacks Investment Research • Feb 26, 2026

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Seeking Alpha • Feb 26, 2026

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. “Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acut.

Business Wire • Feb 26, 2026

Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 25, 2026

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “This year,.

Business Wire • Feb 25, 2026

Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32

Benzinga • Feb 25, 2026